| Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study NA Kennedy, GA Heap, HD Green, B Hamilton, C Bewshea, GJ Walker, ... The lancet Gastroenterology & hepatology 4 (5), 341-353, 2019 | 560 | 2019 |
| HLA-DQA1* 05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn’s disease A Sazonovs, NA Kennedy, L Moutsianas, GA Heap, DL Rice, M Reppell, ... Gastroenterology 158 (1), 189-199, 2020 | 306 | 2020 |
| Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD NA Kennedy, S Lin, JR Goodhand, N Chanchlani, B Hamilton, ... Gut 70 (10), 1884-1893, 2021 | 257 | 2021 |
| Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab NA Kennedy, JR Goodhand, C Bewshea, R Nice, D Chee, S Lin, ... Gut 70 (5), 865-875, 2021 | 174 | 2021 |
| Addressing the indirect effects of COVID-19 on the health of children and young people N Chanchlani, F Buchanan, PJ Gill Cmaj 192 (32), E921-E927, 2020 | 156 | 2020 |
| Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab S Lin, NA Kennedy, A Saifuddin, DM Sandoval, CJ Reynolds, RC Seoane, ... Nature communications 13 (1), 1379, 2022 | 71 | 2022 |
| Classical cardiovascular disease risk factors associate with vascular function and morphology in rheumatoid arthritis: a six-year prospective study A Sandoo, N Chanchlani, J Hodson, JP Smith, KM Douglas, GD Kitas Arthritis research & therapy 15, 1-9, 2013 | 54 | 2013 |
| Adalimumab and infliximab impair SARS-CoV-2 antibody responses: results from a therapeutic drug monitoring study in 11 422 biologic-treated patients N Chanchlani, S Lin, D Chee, B Hamilton, R Nice, Z Arkir, C Bewshea, ... Journal of Crohn's and Colitis 16 (3), 389-397, 2022 | 48 | 2022 |
| Contributors to the CLARITY IBD study. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD NA Kennedy, S Lin, JR Goodhand, N Chanchlani, B Hamilton, ... Gut 70 (10), 1884-1893, 2021 | 47 | 2021 |
| Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic NA Kennedy, M Janjua, N Chanchlani, S Lin, C Bewshea, R Nice, ... Gut 72 (2), 295-305, 2023 | 33 | 2023 |
| Use of infliximab biosimilar versus originator in a pediatric United Kingdom inflammatory bowel disease induction cohort N Chanchlani, K Mortier, LJ Williams, R Muhammed, MKH Auth, ... Journal of pediatric gastroenterology and nutrition 67 (4), 513-519, 2018 | 31 | 2018 |
| Child health systems in the United Kingdom (England) I Wolfe, L Sigfrid, N Chanchlani, S Lenton The Journal of pediatrics 177, S217-S242, 2016 | 28 | 2016 |
| Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic S Lin, LHS Lau, N Chanchlani, NA Kennedy, SC Ng Gut 71 (7), 1426-1439, 2022 | 27 | 2022 |
| Complicated disease and response to initial therapy predicts early surgery in paediatric Crohn’s disease: results from the Porto Group GROWTH Study A Levine, N Chanchlani, S Hussey, T Ziv-Baran, JC Escher, J Amil Dias, ... Journal of Crohn's and Colitis 14 (1), 71-78, 2020 | 26 | 2020 |
| Quality improvement project identifies factors associated with delay in IBD diagnosis GJ Walker, S Lin, N Chanchlani, A Thomas, P Hendy, N Heerasing, ... Alimentary Pharmacology & Therapeutics 52 (3), 471-480, 2020 | 25 | 2020 |
| Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA. 1 and BA. 4/5 variants in patients with inflammatory bowel disease treated with infliximab and … Z Liu, K Le, X Zhou, JL Alexander, S Lin, C Bewshea, N Chanchlani, ... The Lancet Gastroenterology & Hepatology 8 (2), 145-156, 2023 | 24 | 2023 |
| Incidence and prevalence of inflammatory bowel disease in Devon, UK B Hamilton, H Green, N Heerasing, P Hendy, L Moore, N Chanchlani, ... Frontline Gastroenterology 12 (6), 461-470, 2021 | 24 | 2021 |
| Root‐cause analyses of missed opportunities for the diagnosis of colorectal cancer in patients with inflammatory bowel disease C Gordon, D Chee, B Hamilton, NM Heerasing, P Hendy, N Chanchlani, ... Alimentary Pharmacology & Therapeutics 53 (2), 291-301, 2021 | 20 | 2021 |
| Covid-19 vaccine-induced antibodies are attenuated and decay rapidly in infliximab treated patients S Lin, NA Kennedy, A Saifuddin, DM Sandoval, C Reynolds, RC Seoane, ... | 15 | 2021 |
| Informational continuity is integral for successful transition of adolescents to adult care N Chanchlani, M McGEE, JE McDONAGH The Journal of Rheumatology 42 (5), 901-902, 2015 | 15 | 2015 |
